Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

Sponsor
Asan Medical Center
Study ID
NCT01275859
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Letrozole, Lapatinib — DRUG
    Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks

Study Details

Cross-talk between epidermal growth factors and the ER occurs at multiple levels and seems to play a crucial role in breast cancer progression and endocrine resistance.Combined HER1/HER2-targeted therapy with aromatase inhibitors for ER-positive and HER-2 positive postmenopausal breast cancer might enhance response and block emergence of endocrine resistant tumor.

Key Dates

Start date
Sep 30, 2010
Status verified
Aug 2017
Primary completion
Apr 30, 2014
Completion
May 31, 2014

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Letrozole, Lapatinib
    Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks

Primary Outcome Measure

pCR [ Time Frame: 2010 Nov- 2012 May ]

Related Studies